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Abstract
Polymeric nanogels have been sophisticatedly designed promising a new generation of vaccine delivery/
adjuvant systems capable of boosting immune response, a strategic priority in vaccine design. Here, 
nanogels made of mannan or dextrin were evaluated for their potential as carriers/adjuvants in vaccine 
formulations. Since lymph nodes are preferential target organs for vaccine delivery systems, nanogels 
were biotin-labeled, injected in the footpad of rats, and their presence in draining lymph nodes was 
assessed by immunofluorescence. Nanogels were detected in the popliteal and inguinal lymph nodes 
by 24 h upon subcutaneous administration, indicating entrapment in lymphatic organs. Moreover, 
the model antigen ovalbumin was physically encapsulated within nanogels and physicochemically 
characterized concerning size, zeta potential, ovalbumin loading, and entrapment efficiency. The 
immunogenicity of these formulations was assessed in mice intradermally immunized with ovalbumin–
mannan or ovalbumin–dextrin by determining ovalbumin-specific antibody serum titers. Intradermal 
vaccination using ovalbumin–mannan elicited a humoral immune response in which ovalbumin-specific 
IgG1 levels were significantly higher than those obtained with ovalbumin alone, indicating a TH2-type 
response. In contrast, dextrin nanogel did not show adjuvant potential. Altogether, these results 
indicate that mannan nanogel is a material that should be explored as a future antigen delivery system.
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Introduction
Nanotechnology plays a significant role in vaccine development and has emerged as a new 
approach in the design of vaccines. Different polymers have been synthesized or modified for 
biomedical applications.1,2 Polysaccharides have been used to synthesize nanogels; these are nano-
sized hydrophilic three-dimensional macromolecular networks. The properties of nanogels, such 
as flexible mesh, high water content, and high loading capacity, permit the carrying of antigens.3,4 
Nanogels are expected to overcome vaccination hurdles, such as inadequate antigen biodistribu-
tion, short half-life, and limited bioavailability upon administration while also protecting the asso-
ciated antigen from adverse physiologic conditions, such as enzyme degradation and/or physical 
alteration such as aggregation or precipitation.5 An increased interaction between immune cells 
and antigens has been observed when antigens are coupled to nanogels. This increased interaction 
modulates and improves the antigen-specific immune response and is known as the adjuvant effect. 
Antigen-presenting cells (APCs) such as dendritic cells and macrophages are fundamental in initi-
ating and modulating the immune response as they capture, process, and present the antigen to T 
cells.6 T cells may also have adjuvant activity to B cells, measured by assessing the levels and 
isotypic profile of immunoglobulin (Ig)G levels in a secondary immune response. A classic exam-
ple can be the predominant production of IgG2a and IgG1 isotypes, associated with TH1- and TH2-
type immune responses in the murine host, respectively.7 Most adjuvants provide danger signals to 
help elicit an immune response against vaccine antigens. The usage of a nano-particulate antigen 
delivery system may help target the antigen to specialized APCs; there should be no adverse effect 
of the carrier alone.8 When administered intramuscularly or subcutaneously, vaccines are drained 
into regional lymph nodes, where T and B cells may encounter their cognate antigen and coopera-
tively mount a specific immune response and generate memory cells.9 For pathogens such as extra-
cellular bacteria or viruses, an effective vaccine usually induces a strong neutralizing antibody 
response.10 Therefore, the formulation should reach the lymph nodes and establish the appropriate 
cell interactions in order to achieve effective and durable immunity. This formulation should avoid 
using organic solvents and high temperatures so as to preserve the antigenic epitopes.11–13
Although the encapsulation of antigens into polymeric vaccines has been explored, few strate-
gies are currently undergoing clinical evaluation.14 The properties of tunable nanocarriers—includ-
ing material chemistry, size, and shape; surface charge; and hydrophobicity/hydrophilicity—impact 
nanocarrier success in preventive or therapeutic vaccination.3,15,16
Previously, we reported the production and characterization of mannan- or dextrin-based 
nanogels. Polymers are natural, medical grade, and biocompatible. The respective nanogels are 
obtained through a simple methodology and moderate conditions. Despite the mentioned advan-
tages, mannan- or dextrin-based nanogels have never been explored for vaccination purposes. 
Briefly, the hydrophilic natural polymers are modified grafting long alkyl chains to promote 
self-assembly of the amphiphilic polymer in water, leading to the nanogel formation.17,18 Nanogel 
loading with proteins and their release were also reported.19 The internalization of mannan or 
dextrin nanogels in vitro by macrophages20,21 and their ability to carry biologically active 
agents22,23 led us to explore their potential as vaccine delivery/adjuvant systems, using ovalbu-
min (OVA) as a model antigen.24,25 In addition, mannan potentially targets APCs since dendritic 
cells and macrophages express on their surface mannose receptors, which recognizes carbohy-
drates present on the cell walls of infectious agents.
In this work, OVA-nanogel formulations were characterized by size, surface charge, OVA load-
ing and entrapment efficiency. The presence of nanogels in proximal lymph nodes (popliteal and 
inguinal) after subcutaneous administration was evaluated by immunofluorescence and comple-
ment system activation was assessed by western blot. The extent and type of immune response 
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elicited after intradermal administration of the OVA-nanogel formulations were evaluated in mice 
by assessing the production of OVA-specific antibodies and their isotypic profile.
Materials and methods
Materials
Cobra venom factor was purchased from Quidel Corporation (USA), mouse monoclonal antibody 
specific for human C3 from Abcam (UK) and the secondary polyclonal goat anti-mouse IgG anti-
body conjugated with alkaline phosphatase from Dako (Denmark). 5-Bromo-4-chloro-3-indolyl 
phosphate (BCIP), O-(2-aminoethyl)-O′-[2-(biotinylamino)ethyl]octaethylene glycol, sodium 
borohydride, bovine serum albumin (BSA), apyrogenic phosphate buffered saline (PBS), 4-nitro-
phenylphosphate disodium salt hexahydrate and the limulus amebocyte lysate test (E-toxate™) 
were obtained from Sigma (USA). Ketamine (Imalgéne 1000) and xilazine (Rompum) were 
acquired from Bayer (Portugal). Optimal cutting temperature (OCT) compound and streptavidin 
dylight 488 were purchased from Thermo Fisher Scientific (USA) and 2-methyl butane from 
VWR International (France). Goat normal serum (Histostain Plus Blocking Solution) and Alexa 
Fluor® 568 goat anti-mouse IgG were obtained from Invitrogen, Life Technologies (USA). The 
primary antibody mouse anti-rat CD169 (clone ED3) was purchased from Serotec (USA) and 
4′,6-diamidino-2-phenylindole (DAPI) containing mounting media (Vectashield H200; Vector, 
USA). Polymyxin B column and bicinchoninic acid (BCA) protein assay were purchased from 
Pierce (USA), Microcon® Centrifugal Filter Devices, with 100,000 nominal molecular weight 
(Mw), from Millipore (Darmstadt, Germany), Minisart® syringe filters (pore size 0.22 µm) from 
Sartorius Stedim Biotech (Germany) and the molecular-weight protein ladder standard (PageRuler 
Prestained Protein Ladder) from Fermentas (USA). The antibodies goat anti-mouse IgM, IgG1, 
IgG2a, IgG3, and IgA conjugated to alkaline phosphatase human adsorbed were purchased from 
Southern Biotech (USA).
Mannan–vinyl methacrylate (VMA)-SC1622 and dextrin–vinyl acrylate (VA)-SC1618 were syn-
thesized as comprehensively described before. Mannan–VMA-SC16 is composed by the hydro-
philic mannan (Mw 85,000) backbone with grafted vinyl methacrylate (VMA) ester groups, which 
are partially substituted with long alkyl (hydrophobic) chains (SC16) via Michael addition. Dextrin–
VA-SC16 is composed by the hydrophilic dextrin (Mw 2000) backbone with grafted vinyl acrylate 
(VA) ester groups, which are also partially substituted with SC16 chains. In this work, the following 
nanogels were used: (1) mannan–VMA-SC16 with degrees of substitution per 100 mannose resi-
dues of 31 and 20, respectively, for the acrylate groups (DSVMA 31%) and alkyl chains (DSC16 20%) 
and (2) dextrin–VA-SC16 with degree of substitution per 100 dextrin glucopyranoside residues of 
30 and 5, respectively, for the acrylate groups (DSVA 30%) and alkyl chains (DSC16 5%). The sterile 
colloidal dispersion stocks of nanogel were prepared by stirring the lyophilized modified polymer 
(mannan or dextrin) in sterile apyrogenic PBS, pH 7.4, followed by sterilizing filtration with 
Minisart syringe filters (pore size 0.22 µm). The nanogel formation was confirmed by dynamic 
light scattering (DLS).
Complement activation assay
To determine whether nanogels activated the complement cascade, the protocol described by the 
Nanotechnology Characterization Laboratory for qualitative determination of total complement 
activation by Western blot analysis19 was performed. Briefly, equal volumes (50 µL) of human 
plasma from healthy donors, veronal buffer, and sample—mannan or dextrin nanogel colloidal 
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dispersion in PBS (1.0 mg/mL), cobra venom factor as positive control, or PBS as negative con-
trol—were mixed together and incubated for 1 h at 37°C. Proteins were resolved using 10% sodium 
dodecyl sulphate–polyacrylamide gel electrophoresis (SDS-PAGE), and then transferred to a 
Immun-Blot PVDF membrane using the Trans-Blot® SD semidry transfer equipment (Bio-Rad, 
USA). The membranes were incubated for 90 min with a mouse monoclonal antibody specific for 
human C3 diluted 1:1000 followed by washes and incubation with secondary polyclonal goat anti-
mouse IgG antibody conjugated with alkaline phosphatase diluted 1:2000. The membrane was 
finally revealed with BCIP. The C3 cleavage was evaluated by densitometry using image analysis 
software (NIH Image J software, U. S. National Institutes of Health, Bethesda, Maryland, USA).
Biotin-labeled nanogels
The strategy used, in this work, for the conjugation of biotin to nanogels is the covalent binding 
through a conjugate addition reaction (1,4 addition) between the acrylate-functionalized polymer 
(dextrin or mannan) and biotin. The biotin acts as nucleophile added to the β-carbon of the α, 
β-unsaturated carbonyl present in acrylate-functionalized polymer.
In order to label nanogels with biotin, the following solutions were prepared: (1) nanogel solu-
tion—10.0 mg of either mannan–VMA-SC16 or dextrin–VA-SC16 dissolved in 4.0 mL of sterile 
apyrogenic water and (2) biotin solution—6.0 mg of O-(2-aminoethyl)-O′-[2-(biotinylamino)
ethyl]octaethylene glycol dissolved in 2.0 mL of sterile apyrogenic water. These two solutions 
were mixed up and stirred for 72 h at 50°C. Unbound biotin was separated by dialysis using regen-
erated cellulose tubular membranes, with a 1000 nominal molecular weight cut off (OrDial 
D-Clean, Orange Scientific, Belgium) against water for 48 h, with frequent water changes. After 
freezing, the mixture was lyophilized and stored. Biotinylation was confirmed by the reduction in 
signal assigned to acrylate groups upon Proton nuclear magnetic resonance (1H-NMR) analysis, 
due to biotin linkage. Otherwise, biotinylation did not affect the nanogel size distribution, as evalu-
ated by DLS.
Lymph node drainage: immunofluorescence study
Wistar rats were chosen in this study, to avoid difficulties in the collection of the very small lymph 
nodes in mice—the model used in the immunization studies. Twelve Wistar rats (males, 15-week 
old, 320–340 g) were purchased from Charles River (Barcelona, Spain). The animals, kept at the 
animal facilities of the Instituto de Ciências Biomédicas de Abel Salazar (ICBAS), Universidade 
do Porto (U.Porto), Portugal, during the experiments, were divided into two groups (six rats in 
each one) and anesthetized with intraperitoneal injection of ketamine (100 mg/kg) and xilazine 
(10 mg/kg). The rats were injected into the footpad (right side) with 100 µL of biotin-labeled dex-
trin or mannan nanogel (1.0 mg/mL in sterile apyrogenic PBS). The left-side footpad was thus used 
as negative control. Twenty-four hours after injection, the rats were euthanized by decapitation. 
Popliteal and inguinal lymph nodes were collected and embedded in OCT compound, frozen in 
2-methyl butane cooled in liquid nitrogen and stored in a −80°C freezer. Cryosections (4 µm) were 
obtained in a cryostat (Leica CM1850), attached to silane-coated slides, air dried, and stored at 
−80°C before staining.
Cryosections were fixed in cold (−20°C) acetone for 2 min, then in freshly prepared paraform-
aldehyde/lysine/periodate (PLP) fixative for 8 min and finally further treated with 0.1% sodium 
borohydride in PBS—to quench autofluorescence. Nonspecific binding was blocked with 10% 
BSA in PBS for 20 min and goat normal serum for an additional 20 min. For macrophage immu-
nostaining, cryosections were incubated overnight at 4°C with the mouse anti-rat CD169 (a cell 
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surface antigen expressed predominantly by macrophages confined to lymphoid organs only) pri-
mary antibody (clone ED3), diluted at 1:50 in PBS with 5% BSA. Then after, Alexa Fluor 568 goat 
anti-mouse IgG diluted at 1:500 in PBS with 5% BSA was applied for 1 h, at room temperature. 
Biotin-labeled nanogels were stained for 1 h with Streptavidin Dylight 488, diluted 1:200 in PBS 
with 5% BSA, at room temperature. Slides were carefully rinsed with 0.01 M PBS, pH 7.5, after all 
incubations. Finally, slides were counterstained with DAPI containing mounting media Vectashield 
H200, coverslipped, and sealed with nail polish. Cryosections were visualized and photographed 
using an inverted fluorescent microscope (Olympus IX7) coupled with a cooled digital color cam-
era (Olympus DP71).
Preparation and characterization of OVA-nanogel formulations
OVA (Grade III, Mw 45 kDa; Sigma) solutions in PBS were depleted of contaminating endotoxin 
using a polymyxin B column and tested by the limulus amebocyte lysate test (E-toxate™). All 
OVA formulations used in this study tested endotoxin free.
The OVA (0.2 mg/mL) incorporation within nanogels (4.0 mg/mL) in PBS, after 24 h of incuba-
tion at 25°C, was evaluated using an ultrafiltration method—5 min at 10,000g to collect the fil-
trate—using Microcon (100,000) Centrifugal Filter device. The retentate was washed twice with 
PBS. Initial sample and all collected filtrate and retentate samples had a fixed final volume adjusted 
with PBS. Empty nanogel colloidal dispersion (4.0 mg/mL) and OVA solution (0.2 mg/mL) in PBS 
were used as controls and subjected to the same procedure. The OVA association with nanogel was 
evaluated by analyzing initial sample, filtrate and retentate fractions by SDS-PAGE and BCA pro-
tein assay. Each sample (10 µL) was diluted with PBS (10 µL) and proteins were desorbed from the 
nanogel by adding SDS loading buffer (4 µL) followed by 6–10 min of boiling. Samples were 
resolved using 12% or 15% SDS-PAGE, for mannan or dextrin formulations, respectively. Each 
gel run included one lane of a Mw protein ladder standard. Gels were silver-stained. For all sam-
ples, the OVA concentration was determined with BCA protein assay following the manufacturer’s 
instructions. Each sample was assessed in triplicate and the absorbance of the nanogel fractionated 
samples was subtracted from those of the OVA-loaded counterparts. The results were expressed as 
the weight ratio of protein per nanogel (µg/mg). Besides, the loading efficiency was defined as the 
percentage of OVA loaded relating to the initial amount of protein.
Mice immunization
Male BALB/c mice (15-week old) were purchased from Charles River (Barcelona, Spain). 
Animals were kept at the animal facilities of the ICBAS—U.Porto during the experiments. 
Hiding and nesting materials were provided as enrichment. Procedures involving mice were 
performed according to the European Convention for the Protection of Vertebrate Animals used 
for Experimental and Other Scientific Purposes (ETS 123) and 86/609/EEC Directive and 
Portuguese rules (DL 129/92).
Mice were trice-immunized intradermally (prime, first boost and second boost) with 20 µg of 
OVA formulated with one of the following delivery vehicles (100 µL): PBS, mannan, or dextrin 
nanogel (400 µg) in PBS incorporated for 24 h at 25°C. Two additional control groups were used, 
mannan or dextrin (400 µg/100 µL) nanogels in PBS.
Boost immunizations were done 13 and 24 days after priming. Blood samples were collected 
13 days after priming, 11 days after first boost and 28 days after second boost, allowed to clot over-
night at 4°C to prepare serum sample aliquots that were stored at −20°C until used for antibody 
detection.
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Titration of OVA-specific antibody in serum
OVA-specific IgM, IgG1, IgG2a, IgG3 and IgA antibodies were quantified in serum samples by 
enzyme-linked immunosorbent assay (ELISA). In brief, microtiter flat-bottom 96-well plate was 
coated overnight at 4°C with 5 µg/mL OVA solution in PBS (50 µL per well). After washing with 
TST buffer [Tris-buffered saline (10 mM Tris base, 150 mM NaCl), pH 8.0, containing  0.05% 
Tween 20], blocking solution, TST buffer with 2% BSA, was added (200 µL per well) and incu-
bated for 1 h at room temperature. After discarding the block solution, serial dilutions of the serum 
samples in TST with 1% BSA were then plated (50 µL per well) and incubated for 1 h at room 
temperature. After washing with TST buffer, the secondary antibody goat anti-mouse IgM, IgG1, 
IgG2a, IgG3, and IgA conjugated to alkaline phosphatase human adsorbed diluted 1:500 was incu-
bated 1 h at room temperature (50 µL per well). After washing with TST buffer, the bound antibod-
ies were detected by development at room temperature, protected from light, using a substrate 
solution (50 µL per well) of 4-nitrophenylphosphate disodium salt hexahydrate dispersed in 5 mL 
of alkaline phosphatase buffer (50 mM Na2CO3, 1 mM MgCl2), pH 9.8. The reaction was stopped 
by the addition of 0.1 M ethylenediaminetetraacetic acid (EDTA), pH 8.0 (50 µL per well). The 
absorbance was measured at 405 and at 570 nm as reference with a spectrophotometer (Original 
Multiskan Ex; Thermo Electron Corporation, Waltham, MA, USA). The antibody titers were 
expressed as the reciprocal of the highest dilution giving an absorbance of 0.1 above that of the 
control (no serum added).
Statistical analysis
The results were expressed as mean ± standard deviation (SD) for each group and statistical analy-
sis was carried out using one-way analysis of variance (ANOVA) with Bonferroni’s multiple com-
parison post-test using GraphPad Prism version 4.00 for Windows (GraphPad Software, La Jolla, 
CA, USA).
Results and discussions
Nanogels and OVA-nanogel formulations
Nanogels are obtained by dispersion of lyophilized modified polymer in aqueous solution which is 
subsequently sterilized.17,18 OVA loading is done through incubation of OVA with nanogels that are 
then purified. Therefore, the preparation conditions avoid the use of organic solvents, high tem-
peratures or otherwise harsh conditions which would compromise or aggregate the antigen.
The prepared nanogels or OVA-nanogel formulations were characterized regarding their size 
distribution and zeta potential (Table 1).
OVA–mannan formulation presents a mean hydrodynamic diameter and a near neutral surface 
charge, similar to those obtained for empty mannan nanogel. OVA–dextrin formulation presents a 
≈nine times lower diameter and similar zeta potential compared to OVA–mannan. The results 
obtained reveal that OVA incorporation within nanogels (mannan or dextrin) did not alter nanogel 
size or surface charge.
The size of a delivery system can influence its biodistribution and consequently the fate of the 
antigen in vivo. Small particles can easily penetrate the extracellular matrix and enter directly into 
the lymphatic vessels. Larger particles will mainly linger at the administration site as they cannot 
pass through the extracellular matrix.26 The surface charge also plays a significant role in the acti-
vation of the immune response. Thiele et al.27 showed that the uptake of polystyrene nanoparticles 
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by macrophages and dendritic cells can be strongly enhanced in vivo for particles bearing a cati-
onic surface. Interestingly, when comparing the dendritic cell uptake of polystyrene spheres of 100 
and 1000 nm with different surface charge, Foged et al.28 observed that the cationic coating 
increased the uptake of larger particles, while smaller ones seem to undergo equal uptake indepen-
dently to their surface charge.
Following loading of nanogels with OVA, samples were subjected to purification using Microcon 
centrifugal devices to remove free protein, allowing the determination of OVA loading and entrap-
ment efficiency. Initial and fractionated samples were analyzed by SDS-PAGE (Figure 1). No deg-
radation of the protein was detected after the incubation period (Figure 1(a)). As expected, free OVA 
flowed through the ultrafiltration device (Figure 1(b)), allowing effective removal of the non-encap-
sulated protein in nanogel formulations.
Entrapment efficiency can be qualitatively estimated from Figure 1. Comparing mannan (Figure 
1(b)) and dextrin (Figure 1(c)) nanogels, it can be concluded dextrin allows more efficient entrap-
ment. After centrifugation of the mannan formulation, OVA was detected in the filtrate (f) and in 
the first (1w) and second wash (2w). However, some protein still remained in the retentate (r). In 
the case of the dextrin formulation, OVA was not detected in the filtrate nor in the wash fluids. OVA 
was detected in the retentate (r) in amounts roughly comparable to the initially loaded protein.
Table 1. Size (diameter and polydispersity index) and zeta potential measurements obtained at 37°C for 
mannan or dextrin nanogels (4.0 mg/mL in PBS), OVA–mannan or OVA–dextrin formulations  
(OVA 0.2 mg/mL and nanogels 4.0 mg/mL in PBS).
Mannan 
nanogel
OVA–mannan 
nanogel
Dextrin 
nanogel
OVA–dextrin 
nanogel
Diameter (nm) 240.9 ± 6.7 234.3 ± 8.5 23.3 ± 0.4 27.1 ± 1.4
Polydispersity index 0.618 ± 0.099 0.702 ± 0.022 0.495 ± 0.009 0.339 ± 0.028
Zeta potential (mV) −9.69 ± 2.00 −10.90 ± 1.43 −9.92 ± 1.95 −10.10 ± 1.62
OVA: ovalbumin; PBS: phosphate buffered saline; SD: standard deviation.
Values represent mean ± SD (n = 5).
Figure 1. Silver-stained SDS-PAGE gels of (a) OVA (0.2 mg/mL) comparing the freshly prepared (x) with 
the one incubated 24 h at 25°C (y); (b) OVA solution (0.2 mg/mL in PBS), OVA–mannan formulations  
and mannan nanogel (M, 4.0 mg/mL in PBS) and (c) OVA–dextrin formulations and dextrin nanogel  
(D, 4.0 mg/mL in PBS). Formulations were obtained by incorporation (24 h at 25°C) of OVA (0.2 mg/mL) 
within nanogel dispersed in PBS (4.0 mg/mL)—initial sample (i), first filtrate (f), and retentate obtained after 
washing (r): first wash (1w) and second wash (2w).
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Figure 2. Analysis of complement system activation by Western blot for mannan nanogel (M) and dextrin 
nanogel (D). Cobra venom factor was used as positive control (C+) and PBS as negative control (C−). 
The upper band of ~115 kDa corresponds to C3 (α chain) and the lower band ~43 kDa corresponds to 
C3-cleavage product(s) (C3c, iC3b[C3α′]). C3 cleavage was evaluated by densitometry using image analysis 
software (NIH Image J software), after normalizing the percentage of the lower band of the positive 
control as the maximum cleavage that can be achieved (100%): 41 ± 8% for negative control, 33 ± 7% for 
mannan nanogel, and 37 ± 2% for dextrin nanogel.
A BCA protein assay was performed to quantify the protein content of the retentate (after ultra-
filtration), giving 16.6 ± 7.2 and 39.2 ± 4.7 OVA µg/mg for mannan and dextrin nanogels, respec-
tively, corresponding to a loading efficiency of 36.3 ± 6.1% and 78.5 ± 9.3%, respectively. Therefore, 
a much higher loading efficiency was obtained for dextrin formulations.
Complement activation
Complement activation can enhance immune response by promoting chemotaxis, macrophage 
phagocytosis, B-cell activation through CD21 binding and antigen presentation by follicular den-
dritic cells.29 However, excessive inflammation and anaphylaxis are possible serious side effects of 
complement activation.30,31 Therefore, the extent of complement activation induced by nanogels 
was examined in an in vitro assay, using human plasma aliquots pretreated with nanogels.
As demonstrated in Figure 2, mannan or dextrin nanogels raised similar levels of C3-cleavage 
products as the negative control, indicating they did not induce the in vitro activation of the com-
plement cascade. Therefore, it is unlikely they would induce a deleterious inflammatory response 
due to complement activation in vivo.
Nanogel capture by macrophages in lymph nodes
It is generally accepted that vaccine delivery systems (liposomes, microspheres, nanoparticles, 
emulsions) are recognized by APCs and promote uptake of the associated antigen.32 However, their 
migration toward the lymph nodes and subsequent retention, a crucial step in immune response 
initiation, has not been fully explored. The lymph node is a privileged target organ for vaccine deliv-
ery providing an adequate cellular and molecular environment for the activation of B and T cells.
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The pharmacokinetics of nanoparticles to lymphatics from the injection site depends on both the 
physiological structure of interstitial space and lymphatic system and on the nanoparticle physico-
chemical properties such as surface charge, size, or colloidal stability.33 In the lymph nodes, parti-
cles can get mechanically filtered out in the reticular meshwork of the sinuses or be internalized by 
macrophages and/or dendritic cells. Particles not trapped by the first encountered lymph node will 
follow the lymph downstream to the next one.34 One challenge in the development of effective 
vaccine carriers lies on obtaining efficient taken up into lymphatics, retention, and internalization 
by APCs. Reddy et al.35 showed that nanoparticles smaller than 50 nm in diameter are more effi-
ciently transported to regional draining lymph nodes, via interstitial flow, and internalized by 
lymph node DCs. Nanoparticles bigger than 100 nm remain near the administration site, where 
they may be internalized by immature peripheral dendritic cells that then migrate to lymph nodes, 
mature, and present antigen to T cells.36,37
In order to assess the presence of nanogels in the proximal lymph nodes, rats were injected in 
the footpad with biotin-labeled nanogels. Twenty-four hours after administration, popliteal and 
inguinal lymph nodes were collected. Antigens carried to the lymph nodes by the afferent lymph 
must pass a macrophage-rich zone that lies underneath the subcapsular sinus before reaching the B 
cell–rich follicles.38 Subcapsular sinus macrophages by sampling antigens at the lymph–tissue 
interface may function as a first line of APCs.33 These APCs may also display antigens able to be 
directly recognized by lymph node B cells.39,40 Therefore, we assessed whether the nanogels used 
could also target these cells. Cryosections of lymph nodes showed the presence of nanogels in the 
popliteal lymph node (in green on Figure 3) within 24 h of injection.
The presence of nanogels in the inguinal lymph node was verified 24 h after subcutaneous 
administration.
Notably, both nanogels co-localized with macrophages (CD169+), essentially underneath the 
subcapsular sinus; however, mannan seems to penetrate further into the lymph node than dextrin 
nanogels, probably reaching the B cell–rich follicles. As the presence of nanogels in both the pop-
liteal and inguinal lymph nodes was effective for at least for 24 h, it shows an important entrapment 
of the nanogels in these lymphatic organs. Macrophages were shown to retain antigens for even 
longer periods;41 therefore, persistence of antigens delivered in this way may be expected.
Specific antibody response in serum induced by immunization using OVA-nanogel 
formulations
The effect of mannan or dextrin nanogel on the magnitude of the humoral immune response in 
OVA-immunized mice was evaluated by assessing the serum titers of OVA-specific antibodies of 
isotypes IgA, IgG1, IgG2a, IgG2b, IgG3, and IgM. The OVA–mannan formulation leads to an 
increase in the serum levels of OVA-specific IgG1 antibodies elicited by immunization, as com-
pared to OVA alone, indicating that mannan nanogel provided an adjuvant effect (Figure 4).
In contrast, the immunization with OVA–dextrin elicited the production of IgG1 antibodies to 
levels similar to control animals immunized with OVA alone. Mice treated with nanogels alone did 
not present OVA-specific IgG1 antibodies. The immunizations did not raise the serum levels of 
OVA-specific antibodies of the remaining IgG isotypes or of IgA or IgM.
The selective increase in serum IgG1 antibodies indicates that mannan nanogel could favor a 
TH2-type immune response, usually associated with antibody production rather than a cellular 
response as could be inferred from the lack of IgG2a antibodies, associated with a TH1-type 
immune response, typically cell mediated.42,43
A possible strategy to further boost the humoral response and even to achieve cellular response 
would consist on the association with other immunostimulants, either entrapped or covalently 
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attached to the nanogel. This strategy, that is, a synergistic enhancement of the immune reaction, 
which may be reached by combining several adjuvant stimuli, has been reported as effective.44,45 
For example, multifunctional chitosan nanoparticles incorporating the recombinant hepatitis B 
surface antigen and a Toll-like receptor 7 (TLR7) agonist (imiquimod) elicited a specific and pre-
dominant TH1-mediated immune response upon nasal immunization.46
The mannose receptor, expressed by a variety of cell types, including dendritic and macrophage 
cells, is implicated in the recognition and clearance of microorganisms and serum glycoproteins. 
Although being able to entrap larger amounts of protein and being expected to more effectively 
Figure 3. Fluorescence observation of lymph node cryosections stained with anti-CD169 (red)  
to identify macrophages and with streptavidin dylight 488 to identify biotin-labeled nanogels (green) after 
footpad injection of nanogels: (a) popliteal node as negative control (without nanogel injection);  
(b) popliteal node 24 h after footpad injection of mannan nanogels, and (c) popliteal node 24 h after footpad 
injection of dextrin nanogels,. Nuclei are stained in blue. All images are representative of two independent 
experiments. Scale bars: 300 µm.
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drain to the lymphatic system due the smaller particle size, the dextrin nanogel did not bring any 
enhancement of the immune reaction, thus mannan seems to play a relevant functional role, as it 
has been described in the literature.47,48
Conclusion
The results showed mannan or dextrin nanogels to be suitable carriers of protein antigens, shown 
here with OVA as a model antigen. The studied nanogels are not expected to induce major inflam-
matory responses since they did not induce in vitro activation of the complement cascade.
The mannan nanogel (241 nm) presents higher hydrodynamic diameter than the dextrin nanogel 
(23 nm), while a similar zeta potential is observed for both nanogels (around −10 mV). After OVA 
entrapment, size and zeta potential remained almost constant for both formulations. Despite the 
superior size of mannan nanogel, the entrapment efficient of OVA is lower for this nanogel (36.3%) 
compared to dextrin nanogel (78.5%). Regarding the nanogels drainage, both are present in the 
lymph nodes 24 h after administration.
Mannan nanogel, in contrast to dextrin nanogel, showed immunological adjuvant activity on the 
specific immune response to OVA, predominantly of the humoral type.
The simple methodology, moderate conditions, and that the polymers are medical grade, natu-
ral, and biocompatible should all be pointed out as advantages.
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